The use of
glucagon-like peptide-1 (7-36)
amide (GLP-1) receptor agonists for the treatment of
type 2 diabetes mellitus is commonly associated with
nausea and
vomiting. Therefore, the present studies investigated the potential of
GLP-1 receptor ligands to modulate
emesis and feeding in Suncus murinus.
Exendin-4, a selective
GLP-1 receptor agonist, was administered subcutaneously (1-30 nmol/kg) or intracerebroventricularly (0.03-3 nmol) after 12-h of fasting. In other studies, animals were pretreated with the
GLP-1 receptor antagonist,
exendin (9-39), or saline (5 μl) 15 min prior to
exendin-4 (3 nmol, i.c.v.). Behaviour of animals and food and water intake were then recorded for 1-2 h; c-Fos expression was also assessed in the brains of animals in the i.c.v. studies. The subcutaneous administration of
exendin-4 reduced food and water intake (p < 0.001) and induced
emesis in 40% of animals (p > 0.05). The intracerebroventricular administration of
exendin-4 also prevented feeding, and induced
emesis (p < 0.01). In these studies,
exendin (9-39) (30 nmol, i.c.v.) antagonised
emesis induced by
exendin-4 and the increased c-Fos expressions in the brainstem and hypothalamus (p < 0.05), but it was ineffective in reversing the exendin-4-induced inhibition of food and water intake (p > 0.05). These data suggest that
exendin-4 exerts its
emetic effects in the brainstem and/or hypothalamus via
GLP-1 receptors. The action of
exendin-4 to suppress feeding may involve non-classical
GLP-1 receptors or other mechanisms.